Mark Soloway1, Mack Roach. 1. Department of Urology, University of Miami School of Medicine, Miami, Florida 33136, USA. msoloway@miami.edu
Abstract
BACKGROUND: Radical prostatectomy and radiotherapy (RT), both radical therapies, are the standard treatments of curative intent for early prostate cancer. However, these therapies are not curative in all patients and, consequently, a substantial proportion of treated patients remain at risk of disease progression and/or cancer-related death. METHODS: This article presents contemporary data on the incidence of prostate-specific antigen (PSA) and clinical disease progression after primary therapy of curative intent in relation to commonly assessed pretreatment or pathologic disease characteristics. RESULTS: The data highlight the substantial risk of progression for certain patient groups, such as those with Gleason score 8-10, cT3 disease, lymph node metastases, and/or pretreatment PSA levels > 20 ng/mL. CONCLUSIONS: Improved and/or additional treatment options are needed for these patient groups.
BACKGROUND: Radical prostatectomy and radiotherapy (RT), both radical therapies, are the standard treatments of curative intent for early prostate cancer. However, these therapies are not curative in all patients and, consequently, a substantial proportion of treated patients remain at risk of disease progression and/or cancer-related death. METHODS: This article presents contemporary data on the incidence of prostate-specific antigen (PSA) and clinical disease progression after primary therapy of curative intent in relation to commonly assessed pretreatment or pathologic disease characteristics. RESULTS: The data highlight the substantial risk of progression for certain patient groups, such as those with Gleason score 8-10, cT3 disease, lymph node metastases, and/or pretreatment PSA levels > 20 ng/mL. CONCLUSIONS: Improved and/or additional treatment options are needed for these patient groups.
Authors: Amit Roy; Olga Green; Randall Brenneman; Walter Bosch; Hiram A Gay; Jeff M Michalski; Brian C Baumann Journal: Clin Genitourin Cancer Date: 2022-01-11 Impact factor: 3.121
Authors: Eleanor F Need; Howard I Scher; Amelia A Peters; Nicole L Moore; Albert Cheong; Charles J Ryan; Gary A Wittert; Villis R Marshall; Wayne D Tilley; Grant Buchanan Journal: Endocrinology Date: 2009-03-12 Impact factor: 4.736
Authors: Eric T Miller; Karim Chamie; Lorna Kwan; Michael S Lewis; Beatrice S Knudsen; Isla P Garraway Journal: Cancer Med Date: 2016-12-20 Impact factor: 4.452
Authors: Y van Wijk; I Halilaj; E van Limbergen; S Walsh; L Lutgens; P Lambin; B G L Vanneste Journal: Biomed Res Int Date: 2019-06-06 Impact factor: 3.411
Authors: Adebusola Alagbala Ajibade; Jason S Kirk; Ellen Karasik; Bryan Gillard; Michael T Moser; Candace S Johnson; Donald L Trump; Barbara A Foster Journal: PLoS One Date: 2014-02-26 Impact factor: 3.240